2025 North America Adult Vaccine Market Revenue Opportunities Report
Description
The 2025 North America Adult Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in North America are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi S.A. Pfizer leads with innovations in mRNA and protein subunit vaccines, notably expanding their pneumococcal and meningococcal vaccine portfolios. GSK excels with its herpes zoster vaccine Shingrix and influenza vaccines, focusing on advanced adjuvant technologies to enhance efficacy. Merck is prominent with its HPV vaccine Gardasil, MMR, and pneumococcal vaccines, recently investing heavily in U.S. manufacturing, including a new $1 billion plant in North Carolina. Sanofi offers strong presence in influenza and combination vaccines, advancing novel delivery platforms and expanding manufacturing capacities.
Additionally, Seqirus, a business of CSL Limited, operates the largest cell-based influenza vaccine manufacturing facility in the U.S., located in Holly Springs, North Carolina. This facility is pandemic-ready with a capacity to deliver 150 million doses within six months, underscoring CSL’s vital role in influenza prevention in North America. Alongside these leaders, Johnson & Johnson also participates actively in experimental adult vaccines against diseases like Ebola and RSV, broadening the regional market scope. North America remains the largest region for adult vaccine sales globally, supported by these companies' investments in innovation, domestic production, and public-private partnerships.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in North America are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi S.A. Pfizer leads with innovations in mRNA and protein subunit vaccines, notably expanding their pneumococcal and meningococcal vaccine portfolios. GSK excels with its herpes zoster vaccine Shingrix and influenza vaccines, focusing on advanced adjuvant technologies to enhance efficacy. Merck is prominent with its HPV vaccine Gardasil, MMR, and pneumococcal vaccines, recently investing heavily in U.S. manufacturing, including a new $1 billion plant in North Carolina. Sanofi offers strong presence in influenza and combination vaccines, advancing novel delivery platforms and expanding manufacturing capacities.
Additionally, Seqirus, a business of CSL Limited, operates the largest cell-based influenza vaccine manufacturing facility in the U.S., located in Holly Springs, North Carolina. This facility is pandemic-ready with a capacity to deliver 150 million doses within six months, underscoring CSL’s vital role in influenza prevention in North America. Alongside these leaders, Johnson & Johnson also participates actively in experimental adult vaccines against diseases like Ebola and RSV, broadening the regional market scope. North America remains the largest region for adult vaccine sales globally, supported by these companies' investments in innovation, domestic production, and public-private partnerships.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
